Cambridge Healthtech Institute’s 2nd Annual
Cell Therapy Bioproduction
Industrializing Cell Therapies
August 3-4, 2015
Part of CHI's 7th Annual The Bioprocessing Summit
August 3-7, 2015 | Westin Copley Place Hotel | Boston, Massachusetts
Continuing the discussions initiated at last year’s Cell Therapy Bioproduction conference and building upon the industry’s increasing knowledge and experience in this field, we have identified the top challenges that scientists and engineers are struggling with, which range from translation from bench to clinic, to commercial scaling up from 2D to 3D cultures, product characterization and analytics, QC and process validation, as well as commercialization hurdles such as COGS and procurement.
CHI’s Second Annual Cell Therapy Bioproduction aims to open the communication channels between pharma, academia and vendors by presenting first-hand case studies, practical examples, proven concepts and novel technologies to help provide potential solutions to these challenges.
I’m From the Government and I’m Here to Help - Navigating the Global Regulatory Maze for Cellular Therapeutics
Anthony Davies, Ph.D., President, Dark Horse Consulting, Inc.
Qualification of Raw Materials for Cell Therapy
Fouad Atouf, Ph.D., Director, Biologics and Biotechnology, U.S. Pharmacopeia
Sourcing and Qualification of Starting Cellular Materials
Elizabeth Read, Consultant, EJ Read Consulting LLC
Perfused Bioreactor for the Optimization of Human Stem Cell Culture
Veronique Chotteau, Ph.D., Principal Investigator, Cell Technology Group, School of Biotechnology, KTH, Royal Institute of Technology
Cell Expansion and Scaling Up in 3D: Implementing an Optimized, Standardized and Fully Automated Operation
Ohad Karnieli, Ph.D., VP Technology and Manufacturing, Pluristem Therapeutics
Optimization and Clinical Manufacturing of Chimeric Antigen Receptor (CAR) T Cells for Solid Tumors
Pranay D. Khare, Ph.D., Director, Cancer Immunotherapy and Gene Therapy cGMP Facility, Roger Williams Medical Center
Overcoming Comparability and Scale-Up Challenges in Cell Therapy Production
Robert Deans, Ph.D., Executive VP, Regenerative Medicine, Athersys, Inc.
Commercialization of an Autologous Cell Therapy Product (tentative title)
Knut Niss, Ph.D., Sr Technical Project Leader, Novartis Pharmaceuticals Corp.
For more details on the conference,
Sr. Conference Director
Phone: (+1) 816-471-0701
For exhibit & sponsorship opportunities, please contact: